Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab with TACE, RFA, or Cryoablation in HCC and BTC
NCT01853618Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2013
- Primary completion
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in hepatocellular carcinoma (HCC), biliary tract carcinoma (BTC), sponsored by National Cancer Institute. Started May 2013; status: completed.
02
Drugs
tremelimumab
03
Conditions
hepatocellular carcinoma (HCC)biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT01853618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853618.